Datopotamab Deruxtecan, often abbreviated as DATO, represents a notable advancement within targeted cancer care. This novel antibody-drug conjugate pairs an monoclonal immunoglobulin specifically targeting HER2 https://www.targetmol.com/compound/datopotamab